POAI vs. HSCS, NAOV, TMDIF, XWEL, AVGR, SILO, OGEN, ATXI, VCNX, and XCUR
Should you be buying Predictive Oncology stock or one of its competitors? The main competitors of Predictive Oncology include Heart Test Laboratories (HSCS), NanoVibronix (NAOV), Titan Medical (TMDIF), XWELL (XWEL), Avinger (AVGR), Silo Pharma (SILO), Oragenics (OGEN), Avenue Therapeutics (ATXI), Vaccinex (VCNX), and Exicure (XCUR). These companies are all part of the "medical" sector.
Heart Test Laboratories (NASDAQ:HSCS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
17.2% of Heart Test Laboratories shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 2.7% of Heart Test Laboratories shares are held by insiders. Comparatively, 3.4% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Predictive Oncology had 8 more articles in the media than Heart Test Laboratories. MarketBeat recorded 10 mentions for Predictive Oncology and 2 mentions for Heart Test Laboratories. Heart Test Laboratories' average media sentiment score of 0.22 beat Predictive Oncology's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the news media.
Predictive Oncology received 145 more outperform votes than Heart Test Laboratories when rated by MarketBeat users. However, 75.00% of users gave Heart Test Laboratories an outperform vote while only 64.35% of users gave Predictive Oncology an outperform vote.
Heart Test Laboratories has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Heart Test Laboratories, indicating that it is currently the more affordable of the two stocks.
Heart Test Laboratories has a net margin of 0.00% compared to Heart Test Laboratories' net margin of -785.62%. Heart Test Laboratories' return on equity of -104.21% beat Predictive Oncology's return on equity.
Heart Test Laboratories has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
Summary
Heart Test Laboratories and Predictive Oncology tied by winning 7 of the 14 factors compared between the two stocks.
Get Predictive Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Predictive Oncology Competitors List
Related Companies and Tools
